Toxic Side Effects Service
Druggability refers to the potential to develop into a drug, which has carried out the preliminary pharmacodynamics study, early evaluation of pharmacokinetic properties and safety. The research on toxic side effects is an important part of druggability research. Toxic side effect is the result of the interaction between the drug and the non-target, which is the negative effect associated with pharmacodynamics. The efficacy and toxic side effect of drugs often lead to the failure of drug research and development at the clinical stage, resulting in huge losses. As a reliable partner in drug development, Creative Biolabs provides toxicological evaluation services at various levels, including genotoxicity, in vitro cytotoxicity and in vivo toxicity.
Creative Biolabs assists the client in conducting toxicological evaluation, which is strictly in accordance with GLP requirements and can identify the potential toxic effects and target organs of the drug candidates, providing a reference direction for possible clinical adverse reactions.
We provide but are not limited to:
- Genotoxicity Evaluation Service. Genotoxicity refers to the toxic effect caused by the physical and chemical factors of drug candidates acting on an organism and causing various damages to its genetic material at the chromosomal, molecular and base levels.
- Genetic mutations (Ames test). Ames test is a common method to detect genetic mutations in chemical substances.
- Single Cell Gel Eletrophoresis (SCGE). SCGE can not only be used for the detection of living cell DNA, but also for the analysis of dead cell DNA, so that SCGE can not only study the biological effects under low dose, but also can be used for the study of biological effects under high dose. SCGE can provide information on DNA repair ability at the same time. SCGE service is very suitable for evaluating the genotoxicity of the drug candidates.
- Micronucleus test.
- Chromosome aberration test.
- In vitro cytotoxicity. Creative Biolabs can assist customers to study the in vitro cytotoxicity of candidate drugs.
- Half maximal inhibitory concentration(IC 50). The IC50 service helps customers understand how much of a drug candidate inhibits certain biological processes or certain substances in the process, such as enzymes, cell receptors, or microorganisms. IC50 value can be used to measure the ability of drug induced apoptosis.The stronger the induction ability is, the lower the value will be. This service can reverse indicate the tolerance degree of a certain cell to the drug candidate.
- In vivo toxicity.
- Multiple DRF.
- A single MTD.
The popular services:
- The high-throughput screening (HTS) and high-content screening (HCS) platform is a comprehensive solution for full-automatic, high-speed and high-resolution imaging screening, which can meet a variety of needs in the development of new drugs. The platform captures a large amount of information about genes, proteins and other cellular components in a single experiment to determine their biological activity and potential toxicity. This platform based on high-throughput screening and high-content screening is a common technical platform for drug toxic side effect evaluation.
The Creative Biolabs HTS/HCS platform is equipped with a variety of advanced equipment and data processing system to achieve the full automation, providing strong support for a reliable study of toxic side effect.
References
- Otabe A, et al. Mutagenicity and genotoxicity studies of aspartame. Regul Toxicol Pharmacol. 2019, 103:345-351.
- Aykul S, et al. Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. Anal Biochem. 2016, 508:97-103.
*For Research Use Only. Not for use in diagnostic procedures.